CeeNU 10 mg capsules

Each capsule contains 10 mg of lomustine.

Excipients with known effect: Each capsule contains 213.87 mg of mannitol.

Therapeutic indications

CeeNU is indicated as palliative therapy to be employed in addition to other modalities, or in established combination therapy with other approved chemotherapeutic agents in the following:

1. Brain Tumours - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.

2. Hodgkin's Disease - as a secondary therapy.

3. Advanced Lung Carcinoma - for small cell carcinoma CeeNU is effective in combination with other appropriate neoplastic agents, particularly cyclophosphamide. Patients who have demonstrated delayed hypersensitivity competence in pretreatment testing are usually more responsive to therapy.